Dianthus Therapeutics Shares Slide as Sanofi Halts Key Clinical Trial

Key Facts

In a move that underscores the high sensitivity of the biotech sector to clinical trial outcomes, Dianthus Therapeutics shares faced notable selling pressure. According to reports, the decline followed Sanofi's decision to halt its Phase 3 study of Riliprubart, a treatment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Analysts view this drop as a secondary market reaction to the negative clinical developments at Sanofi.

This pressure comes as investors closely monitor competition in the CIDP treatment market, where Sanofi previously indicated that the halt followed an efficacy assessment, impacting companies developing similar therapeutic platforms. Per market data, Sanofi's stock (SAN.PA) closed at 76.59 EUR on June 12, 2026, fluctuating between a low of 75.56 EUR and a high of 76.89 EUR during the session.

Traders should watch for technical support levels for Dianthus in upcoming sessions to gauge market absorption, especially with SAN.PA stabilizing at 76.59 EUR (close June 12, 2026). Looking at the economic calendar, there are no direct biotech sector catalysts scheduled for the next seven days, leaving price action dependent on additional analyst commentary and healthcare sector capital flows.